Pretransplant and posttransplant treatment of hepatitis C virus infection with protease inhibitors

Current Opinion in Organ Transplantation

Volumn 18, Issue 3, 2013, Pages 271-278

  Londoño, Maria Carlota ^a   Crespo, Gonzalo ^a   Forns, Xavier ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Boceprevir; IFN free regimens; Telaprevir

Indexed keywords

BOCEPREVIR; CYCLOSPORIN A; EVEROLIMUS; INTERFERON; INTERLEUKIN 28B; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TACROLIMUS; TELAPREVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; GENOTYPE; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NEUTROPENIA; PATIENT SELECTION; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; POSTOPERATIVE CARE; PREOPERATIVE CARE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER TRANSPLANTATION; OLIGOPEPTIDES; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROLINE; PROTEASE INHIBITORS;

MLCS; MLOWN;

EID: 84879932927     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283614aca     Document Type: Review

References (47)

1. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687.
2. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250-256.
3. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
4. Saxena V, Terrault N. Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies. Curr Opin Organ Transplant 2012; 17:216-224.
5. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39:389-396.
6. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009; 50:719-728.
7. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42:255-262.
8. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355.
9. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis c after liver transplantation. Hepatology 2012; doi: 10.1002/hep.25976. [Epub ahead of print]
10. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9:905-915.
11. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142:1373-1383.
12. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant 2011; 11:1051-1057.
13. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
14. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
15. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
16. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
17. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
18. Hezode C, Dorival C, Zoulim F, et al. Safety and efficacy of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in 455 cirrhotic non responders. Week 16 analysis of the French early access program (ANRS CO20-CUPIC) in real-life setting. Hepatology 2012; 56 (4 Suppl.):217A. [abstract].
19. Carrion JA, Navasa M, Garcia-Retortillo M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132:1746-1756.
20. Verna EC, Terry N, Lukose T, et al. High early response rates with protease inhibitor triple therapy in a multicenter cohort of HCV-infected patients awaiting liver transplantation. Hepatology 2012; 56 (4 Suppl.):218A.
21. Gallegos-Orozco JF, Chervenak AE, Carey EJ, et al. Liver transplant center focused experience with peginterferon alfa-2a, ribavirin and telaprevir therapy in patients with genotype 1 hepatitis C cirrhosis. Hepatology 2012; 2012 (4 Suppl.):218A.
22. Soriano V, Gane EJ, Angus P, et al. Efficacy and safety of the interferon (IFN)-free combination of BI 201335 + BI 207127 ± ribavirin (RBV) in treatment-naïve patients with HCV genotype (GT) 1 infection and compensated liver cirrhosis: Results from the SOUND-C2 study. Hepatology 2012; 56 (4 Suppl.):234A. [abstract].
23. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216-224.
24. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55:742-748.
25. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2012; 368:34-44.
26. Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2012; 368:45-53.
27. Kowdley K, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. (LB Abstract). AASLD 2012.
28. Berenguer M, Aguilera V, Rubin A, et al. Comparison of two noncontemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol 2012; 56:1310-1316.
29. Rabie R, Mumtaz K, Renner EL. Efficacy of antiviral therapy for hepatitis C post liver transplant on cyclosporine versus tacrolimus: a systematic review and meta-analysis. JT Liver Transpl 2013; 19:36-48.
30. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139:1577-1585.
31. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53:317-324.
32. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011; 55:692-701.
33. Crespo G, Carrion JA, Coto-Llerena M, et al. Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. J Gastroenterol 2012.[Epub ahead of print]
34. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49:274-287.
35. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142:1132-1139.
36. Veldt BJ, Poterucha JJ, Watt KD, et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant 2008; 8:2426-2433.
37. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8:679-687.
38. McCaughan GW. New therapies against HCV: expected risks and challenges associated with their use in the liver transplant setting. J Hepatol 2012; 57:1361-1367.
39. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54:20-27.
40. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56:1622-1630.
41. Barritt ASt, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142:1314-1323.
42. Aqel B, Carey EJ, Byrne TJ, et al. Multicenter preliminary experience utilizing boceprevir with pegylated interferon and ribavirin for treatment of recurrent hepatitis C genotype 1 after liver transplantation. Hepatology 2012; 56 (4 Suppl.):530A. [abstract].
43. Burton JR Jr, Everson GT, O'Leary JG, et al. A multicenter study of protease inhibitor-triple therapy in HCV-infected liver transplant recipients: report from the CRUSH-C group. Hepatology 2012; 56 (4 Suppl.):279A. [abstract].
44. Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56:5728-5734.
45. Werner CR, Egetemeyr DP, Lauer UM, et al. Short report: Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study providing safety and efficacy. Liver Transpl 2012; 18:1464-1470.
46. Coilly A, Roche B, Dumortier J, et al. Efficacy and safety of protease inhibitors for hepatitis C recurrence after liver transplantation: a first multicentric experience. Hepatology 2012; 56 (4 Suppl.):194A. [abstract].
47. Fontana RJ, Hughes EA, Appelman H, et al. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18:1053-1059.